- Home
- PFLT vs PSNL Comparison
PFLT vs PSNL Comparison
Compare PFLT & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFLT | PSNL |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 892.0M | 854.8M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | PFLT | PSNL |
|---|---|---|
| Price | $9.17 | $10.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $10.75 | $10.71 |
| AVG Volume (30 Days) | 923.0K | ★ 1.8M |
| Earning Date | 11-24-2025 | 11-04-2025 |
| Dividend Yield | ★ 13.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $261,427,000.00 | $69,103,000.00 |
| Revenue This Year | $13.24 | N/A |
| Revenue Next Year | $7.22 | $20.33 |
| P/E Ratio | $12.86 | ★ N/A |
| Revenue Growth | ★ 40.28 | N/A |
| 52 Week Low | $8.40 | $2.83 |
| 52 Week High | $11.50 | $11.40 |
Technical Indicators
Market Signals| Indicator | PFLT | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 54.06 | 58.50 |
| Support Level | $9.08 | $9.34 |
| Resistance Level | $9.37 | $11.40 |
| Average True Range (ATR) | 0.21 | 0.83 |
| MACD | 0.01 | 0.18 |
| Stochastic Oscillator | 63.20 | 70.05 |
Price Performance
Historical ComparisonAbout PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generate revenue in the form of interest income on the debt securities and dividends.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.